Home TMU FAQ Sitemap
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202101017 Non-Interventional Collecting Evidences For ILD in Taiwan: Optimized Novel Therapy Interstitial lung disease SHH Pulmonary Medicine Tzu-Tao Chen Yuting Yeh 02-6620-2589 #15315
N202201024 An open-label study to evaluate the effectiveness and safety of EZYPRO® in atrial fibrillation detection in nearly embolic stroke of undetermined source (ESUS) patient Atrial fibrillation SHH Neurology Lung Chan Yuting Yeh 02-6620-2589 #15315
N202205015 A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) Ischemic stroke SHH Neurology Lung Chan Yuting Yeh 02-6620-2589 #15315
N202305029 A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA Ischemic stroke SHH Neurology Lung Chan Yuting Yeh 02-6620-2589 #15315
N201905120 A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2) Lung Cancer SHH Pulmonary Medicine Po-Hao Feng Yuting Yeh 02-6620-2589 #15315
N202303137 A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients. Atopic Dermatitis SHH Dermatology Chia-Lun Chou Yuting Yeh 02-6620-2589 #15315
N202102065 Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) Breast Cancer SHH Hematology and Oncology Tsu-Yi Chao Yuting Yeh 02-6620-2589 #15315
N202307004 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy Breast Cancer SHH Hematology and Oncology Tsu-Yi Chao Yuting Yeh 02-6620-2589 #15315
N202012037 SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Breast Cancer SHH Hematology and Oncology Wei-Hong Cheng Yuting Yeh 02-6620-2589 #15315
N202104068 A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients with Advanced Solid Malignancies Solid tumors SHH Hematology and Oncology Wei-Hong Cheng Yuting Yeh 02-6620-2589 #15315
1 2 5 6 7 8 9 10 11 12 13 14 / 14

TOP